CVS Health Corporation (CVS) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call shows strong financial performance, with increased EPS guidance, revenue growth, and significant savings from negotiations. The Q&A reveals confidence in overcoming challenges, such as Medicare Advantage rates and FTC regulations, while highlighting strategic investments and market share growth. Despite some uncertainties, the overall sentiment is positive, suggesting a likely stock price increase.
Key Financial Performance
Adjusted Operating Income (Q4 2025) $2.6 billion, adjusted earnings per share of $1.09. Modest decline from the prior year quarter due to expected decline in adjusted operating income in the Health Care Benefits segment, driven by changes in the seasonality of the Medicare Part D program due to the impact of the Inflation Reduction Act.
Full Year 2025 Adjusted EPS $6.75, exceeding initial expectations by approximately 15%. Reasons include improved operations and financial performance.
Operating Cash Flow (Full Year 2025) $10.6 billion, exceeding expectations due to strong financial performance and working capital efficiencies.
Aetna Business Adjusted Operating Income Improvement Over $2.6 billion year-over-year improvement. Reasons include refreshed leadership, improved culture, and strengthened capabilities.
Full Year 2025 Revenue Over $400 billion. Driven by growth across all operating segments.
Q4 2025 Revenue Over $105 billion, an increase of over 8% year-over-year. Driven by growth across all operating segments.
Health Care Benefits Segment Revenue (Q4 2025) Over $36 billion, an increase of over 10% year-over-year. Driven by growth in the Government business, largely due to the impact of the IRA on the Medicare Part D program.
Health Services Segment Revenue (Q4 2025) Over $51 billion, an increase of 9% year-over-year. Driven by pharmacy drug mix and brand inflation, partially offset by continued pharmacy client price improvements.
Pharmacy & Consumer Wellness Segment Revenue (Q4 2025) Nearly $38 billion, an increase of over 12% year-over-year. Driven by pharmacy drug mix and increased prescription volume, including incremental volume from the Rite Aid transaction.
Same-Store Pharmacy Sales (Q4 2025) Grew over 19% year-over-year. Driven by pharmacy drug mix and a nearly 10% increase in same-store prescription volumes.
Aetna Network Negotiations Savings Over $235 billion in savings for members and clients. Achieved through network negotiations.
Caremark Drug Manufacturer Negotiations Savings $45 billion in annual savings. Achieved through negotiations with drug manufacturers.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Signify Health: Expanded in-home health evaluations, serving over 3.5 million consumers annually, with 500,000 brief connections and 100,000 urgent escalations.
Oak Street Health: Focused on expanding patient base and positioning for long-term sustainability.
HUMIRA biosimilar strategy: Achieved 96% adoption of low-cost biosimilars, saving $1.5 billion for clients and members.
Aetna's market recognition: Received the inaugural Press Ganey Health Plan of the Year award for high-quality offerings and innovation.
Caremark's market adaptation: Adapted to regulatory changes and supported transparency legislation, including the TrueCost model.
Financial performance: Delivered $2.6 billion in adjusted operating income for Q4 2025 and $6.75 adjusted EPS for the year, exceeding expectations.
Pharmacy & Consumer Wellness: Achieved nearly $38 billion in Q4 revenue, driven by increased prescription volume and favorable drug mix.
Cash flow: Generated $10.6 billion in operating cash flow for 2025, surpassing initial expectations.
Medicare Advantage advocacy: Advocated for better funding to ensure program sustainability and access.
Cost-based reimbursement transition: Completed transition to a cost-based reimbursement model, enhancing transparency and stability.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Medicare Advantage advanced rate notice: The proposed rate does not match the level of medical cost trend in the industry, potentially impacting funding adequacy, access, and sustainability of the program.
Branded drug price increases: Branded drug manufacturers have made over 750 price increases in 2026, adding $25 billion in costs to the healthcare system without added value, creating strain on affordability.
Regulatory changes in the commercial market: Recent regulatory changes are manageable but require adaptation, particularly in pharmacy benefit management and transparency.
Medicare Part D program seasonality changes: Changes in the seasonality of the Medicare Part D program due to the Inflation Reduction Act have led to adjusted operating income declines in the Health Care Benefits segment.
Risk adjustment deterioration in Individual Exchange business: Deterioration in risk adjustment position in the Individual Exchange business has negatively impacted financial performance.
Flu activity impact: Increased flu activity late in the quarter required additional provisions, impacting the medical benefit ratio.
Pharmacy reimbursement pressure: Continued pharmacy reimbursement pressure has affected financial performance in the Pharmacy & Consumer Wellness segment.
Elevated medical cost trends: Medical cost trends remain elevated across all products, impacting financial performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Full Year 2026 Adjusted EPS Guidance: Reaffirmed guidance range of $7 to $7.20.
Medicare Advantage Program: Commitment to margin recovery in the Medicare business while ensuring a sustainable and compelling product offering. Advocacy for more appropriate funding to ensure adequate access and stability.
Oak Street Health Expansion: Focused on expanding the number of patients served to position for a more sustainable and attractive business over the long term.
Pharmacy & Consumer Wellness Segment: Established a new trajectory of at least flat earnings annually starting in 2026.
Cash Flow from Operations for 2026: Updated outlook to at least $9 billion, reflecting certain payments shifted from 2026 into late 2025 and underlying outperformance.
Revenue Guidance for 2026: Reaffirmed guidance for full year 2026 revenue of at least $400 billion.
Medical Cost Trends: Experience in 2025 supports trend assumptions underlying 2026 guidance.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividends distributed in 2025: Over $3 billion in dividends were distributed to shareholders in 2025.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How should we think about the potential impact of the preliminary 2027 Medicare Advantage rates on the company's trajectory to return to target margins by 2028?
A:The company remains committed to Medicare recovery and expects to continue making progress into 2026. Despite the preliminary 2027 rates being disappointing, the company does not see this impacting its long-term enterprise guidance provided in December during the Investor Day. The strategy for 2027 remains unchanged, and the company is confident in its ability to drive the Medicare business back to target margins.
Q:What is the company's view on the FTC's proposed regulations and their impact on the PBM business?
A:The company believes the PBM value remains intact and that it will continue to earn fair margins for the value it delivers. While the company cannot comment on specifics of the FTC discussions, it has been leading market changes with initiatives like TrueCost and CostVantage, which align with the proposed regulations. The company sees these changes as an opportunity to accelerate adoption of its transparent pricing models.
Q:What is the company's strategy for gaining market share in the pharmacy and consumer wellness (PCW) segment?
A:The company is focused on delivering value, driving loyalty, and improving customer experience through localized assortments, technology, and AI. It has successfully transitioned to cost-based reimbursement models and integrated Rite Aid assets, welcoming 9 million new patients and 3,500 colleagues. The company aims to expand its role in customers' everyday health and retail convenience while driving operational efficiencies.
Q:What are the drivers behind the revised medical membership numbers and expectations for commercial group and ASO membership?
A:The company attributes the revised medical membership numbers to better-than-expected retention and innovative products. The commercial business has reached its highest membership level in a decade, driven by growth in the self-funded business and disciplined pricing in fully insured segments. The company expects continued strong performance in the commercial segment.
Q:How are Medicaid rates and trends performing relative to expectations for 2026?
A:The Medicaid business is performing in line with expectations, with strong rate advocacy execution in 2025 and a cautious but positive outlook for 2026. The company is focused on maintaining adequate rates and providing clinical and operational excellence.
Q:What are the company's expectations for medical loss ratio (MLR) across its business segments in 2026?
A:The company expects margin improvement in Medicare due to disciplined pricing and repricing in group MA. Medicaid margins are expected to remain stable, while the commercial business is expected to perform well due to pricing discipline and innovative products. Trends remain elevated but are in line with expectations.
Q:What are the company's plans for technology investments in 2026, and what efficiencies are expected?
A:The company is investing in AI and technology to reimagine the healthcare experience, improve consumer engagement, and drive operational efficiencies. It is developing an open engagement platform to connect with consumers and improve healthcare quality while lowering costs. The company plans to announce new product launches and partnerships in the coming quarters.
Q:What is the company's margin performance and expectations for each subsegment in the health insurance business?
A:The company expects continued margin improvement in Medicare, stable margins in Medicaid, and strong performance in the commercial business. The focus remains on disciplined pricing, innovative products, and maintaining strong fundamentals across all segments.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the FTC discussions, citing ongoing conversations. Additionally, they did not provide precise margin figures or trends for each subsegment in the health insurance business, instead offering general directional guidance.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Advantage program
Brand
CVS Pharmacy
TrueCost
ability competition
authorization
award
care experience
care provider
care system
change market
client member
client need
confidence
connection
consumer engagement
distinction
drug manufacturer
encounter
enterprise
experience health
goal
health care
health member
health outcome
home
interoperability
legislation transparency
manufacturer price
medicine
member care
member client
offering
patient condition
pharmaceutical
price increase
professional
rate notice
result income
saving client
senior
system value
treatment
CVS Transcript
CVS Health Corporation (CVS) Q4 2025 Earnings Call Transcript
Positive2-10
The earnings call shows strong financial performance, with increased EPS guidance, revenue growth, and significant savings from negotiations. The Q&A reveals confidence in overcoming challenges, such as Medicare Advantage rates and FTC regulations, while highlighting strategic investments and market share growth. Despite some uncertainties, the overall sentiment is positive, suggesting a likely stock price increase.
CVS Health Corporation (CVS) Q3 2025 Earnings Call Transcript
Positive10-29
The earnings call summary presents a positive outlook with increased guidance for EPS and revenue, strong revenue growth across all segments, and improved MBR. The Q&A section reveals confidence in future growth, despite some headwinds. The company's strategic initiatives, such as TrueCost and CostVantage, are progressing well, and management's efforts to address challenges are apparent. However, the goodwill impairment charge and some unclear responses are minor concerns. Overall, the positive aspects outweigh the negatives, suggesting a positive stock price movement in the next two weeks.
CVS Health Corporation (CVS) Q2 2025 Earnings Call Transcript
Unknown8-6
The earnings call reveals mixed signals: strong revenue growth in pharmacy and consumer wellness, yet a decline in health services operating income. Positive elements include increased EPS guidance and strong cash flow. However, concerns about reimbursement pressures, unclear future guidance, and mixed Q&A responses temper optimism. The stock price is likely to remain neutral, with no significant short-term catalysts identified.
CVS Health (CVS) Q1 2025 Earnings Call Transcript
Positive5-1
CVS Health's strong financial performance across all segments, including a 7% revenue increase and improved medical benefit ratio, indicates robust operational health. The successful biosimilar market initiative and strategic priorities in digital strategy and cost efficiency further bolster the positive outlook. Despite some concerns about Medicare trends and unclear management responses in the Q&A, the overall sentiment remains positive, with promising projections for 2025 and a substantial dividend return. The lack of a share buyback program is a minor drawback, but the company's financial health and strategic initiatives outweigh these concerns.
CVS Slides
CVS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
